Skip to main content
. Author manuscript; available in PMC: 2021 Jun 4.
Published in final edited form as: Curr Med Chem. 2020;27(25):4181–4193. doi: 10.2174/0929867326666191001125101

Fig. (3).

Fig. (3).

Treating Age-Related Macular Degeneration (AMD) with an aptamer. A: Macugen or VEGF antibodies target Vascular Endothelial Growth Factor (VEGF) that induces neovascularization and vision loss in AMD. B: Aptamer or antibody-based VEGF inhibitors are injected into the vitreous space to bind VEGF in the eye, prevent it from binding to its target receptor and thereby inhibit neovascularization, effectively treating AMD.